Onyx Weight Loss review

Onyx makes a deliberate trade: a small nurse-practitioner-led clinic that names its founders, its clinicians and its dispensing pharmacy, prices each molecule plainly, and reaches only nine states. Sermorelin and NAD⁺ are both $299 a month, a premium price: you are paying for a named, small care team rather than a national platform's scale. Whether that premium is worth paying is a judgment about what you want from the clinical relationship, not a pricing error.

Onyx Weight Loss is a telehealth clinic based at 119 Poplar Pointe Drive in Mooresville, North Carolina, founded by Tasha Vangile, FNP-C and Madalyn Vangile, RN, with Stephanie Robison, APRN-CNP as a second nurse practitioner and a team of registered nurses, a nutrition coach and a clinical coordinator. Its menu runs GLP-1 and GLP-1/GIP weight-loss plans (from $228/month and $280/month, with a $99/month microdosing option), phentermine, lipotropic and B12 injections, a peptides shelf of sermorelin, NAD⁺, GHK-Cu, glutathione and PT-141, low-dose naltrexone, bioidentical hormone replacement including testosterone, and nutrition coaching. Medication is dispensed through a named partner, Strive Pharmacy.

Clinician-led and consultation-first: you book a free consultation with a nurse practitioner, complete an intake and consent form at least 48 hours ahead, are evaluated by video, and medication with any supplies needed ships to your home if a plan is appropriate. The distinguishing feature is scale in the other direction — this is a named team with stated careers rather than an anonymous provider network behind a quiz, and the site names its dispensing pharmacy. Nutrition coaching exists as a separate service rather than being bundled into a plan price, which is at least honestly presented. The constraints are structural. Coverage is nine states — North Carolina, Colorado, Nebraska, Iowa, Pennsylvania, Virginia, Vermont, New Hampshire and Maine — shown on a map image rather than a text list, and the map's own caption omits Nebraska, so confirm your state. No LegitScript certification is claimed; the credentialing on the site is local business awards. The hormone line starts with a $199 comprehensive assessment that includes a 46-plus-biomarker lab panel and a virtual review, but nothing comparable is described for the peptide line. Its GLP-1 pages also never name semaglutide or tirzepatide directly, describing the plans by mechanism instead, and the compounded status is implied by the Strive Pharmacy relationship rather than stated.

Sermorelin is $299/month and NAD⁺ is $299/month, each stated on its own product page. The rest of the peptide shelf is priced too: GHK-Cu starting at $199/month, PT-141 nasal spray at $299, and glutathione, sold as a nasal spray, at $129/month. Its GLP-1 plans start at $228/month and $280/month and a microdosing option is $99/month; those are entry-tier figures with no dose-escalation pricing published — a limitation likely to apply to the peptide line too, so ask whether $299 holds as a provider adjusts your dose. The sermorelin and NAD⁺ figures sit well above the usual range: comparable sermorelin sits between $149 and $195 a month at several national platforms, and comparable NAD⁺ between $149 and $219. What Onyx offers in exchange is a small named care team and a named pharmacy, which is a real thing to buy but is not a price advantage. Labs are priced only for the hormone line ($199 assessment with a lab panel), so budget for them separately if your peptide protocol needs monitoring.

Compounded; not FDA-approved. Prescription required only if a licensed provider finds it appropriate. Onyx's site does not state the compounded status explicitly — it is implied by its Strive Pharmacy partnership, Strive being a known compounding pharmacy — and compounded preparations are not reviewed by the FDA for purity and potency the way approved drugs are. On evidence, the five-molecule shelf runs across very different tiers. Sermorelin is a GHRH analog acting on your own pituitary, a real mechanism with thin long-term human outcome data. Injected NAD⁺ has no controlled human outcome trials at all; the oral precursors NR and NMN are the studied forms and what they show is a raised blood NAD⁺ level, a biomarker rather than a benefit. GHK-Cu is a copper-binding tripeptide with a genuinely interesting cell and animal literature on collagen synthesis and wound repair, and essentially no controlled human outcome data behind the claims made for it. Glutathione is in the same position, and a nasal spray adds a route with even less study behind it. PT-141 (bremelanotide) is the exception: an FDA-approved drug, but for one narrow indication — acquired, generalized hypoactive sexual desire disorder in premenopausal women — so a compounded nasal spray prescribed to anyone else is off-label use of an approved molecule in an unapproved form. Individual results vary.